全文获取类型
收费全文 | 177篇 |
免费 | 10篇 |
专业分类
儿科学 | 20篇 |
基础医学 | 14篇 |
口腔科学 | 2篇 |
临床医学 | 20篇 |
内科学 | 66篇 |
神经病学 | 10篇 |
特种医学 | 3篇 |
外科学 | 3篇 |
综合类 | 2篇 |
预防医学 | 9篇 |
眼科学 | 1篇 |
药学 | 16篇 |
肿瘤学 | 21篇 |
出版年
2022年 | 6篇 |
2021年 | 5篇 |
2020年 | 5篇 |
2019年 | 7篇 |
2018年 | 1篇 |
2017年 | 3篇 |
2015年 | 1篇 |
2014年 | 3篇 |
2013年 | 6篇 |
2012年 | 6篇 |
2011年 | 12篇 |
2010年 | 8篇 |
2009年 | 6篇 |
2008年 | 9篇 |
2007年 | 9篇 |
2006年 | 13篇 |
2005年 | 9篇 |
2004年 | 7篇 |
2003年 | 5篇 |
2002年 | 11篇 |
2001年 | 17篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 5篇 |
1997年 | 1篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
排序方式: 共有187条查询结果,搜索用时 296 毫秒
1.
2.
Botrocetin isolated from the venom of Bothrops jaracara has been shown by others to induce binding of von Willebrand Factor to glycoprotein Ib and thereby produce platelet agglutination in a wide range of animal species. We have found that botrocetin also facilitates the agglutination of megakaryocytes and have used this property to develop a method to isolate megakaryocytes from rat bone marrow. When botrocetin is added to a mixture of rat bone marrow, rat platelets, and rat plasma, coagglutination of megakaryocytes and platelets occurs. The agglutinated complexes, containing > 95% of the megakaryocytes, may then be separated from the remaining marrow cells by filtration. Megakaryocytes account for 39% (range 30%-48%) of the isolated cells and 83% (range 77%-88%) of the isolated cell mass. This method allows the virtually complete removal of megakaryocytes from bone marrow as well as their isolation to a high degree of purity. It should provide a useful, inexpensive, general method for the rapid isolation of megakaryocytes from multiple, small marrow samples from a wide range of species. 相似文献
3.
Alphonse G Taghian Rita Abi-Raad Sherif I Assaad Adrian Casty Marek Ancukiewicz Eren Yeh Peryhan Molokhia Khaled Attia Timothy Sullivan Irene Kuter Yves Boucher Simon N Powell 《Journal of clinical oncology》2005,23(9):1951-1961
PURPOSE: It has been hypothesized that tumors with high interstitial fluid pressure (IFP) and/or hypoxia respond poorly to chemotherapy (CT) because of poor drug delivery. Preclinical studies have shown that paclitaxel reduces the IFP and improves the oxygenation (pO(2)) of tumors. Our aim is to evaluate the IFP and pO(2) before and after neoadjuvant CT using sequential paclitaxel and doxorubicin in patients with breast cancer tumors of >/= 3 cm. PATIENTS AND METHODS: Patients were randomly assigned, according to an institutional review board-approved phase II protocol, to receive neoadjuvant sequential CT consisting of either four cycles of dose-dense doxorubicin at 60 mg/m(2) every 2 weeks followed by nine cycles of weekly paclitaxel at 80 mg/m(2) (group 1) or vice versa, with paclitaxel administered before doxorubicin (group 2). Patients were re-evaluated clinically and radiologically. The IFP (wick-in-needle technique) and pO(2) (Eppendorf) were measured in tumors at baseline and after completing the administration of the first and second drug. RESULTS: IFP and pO(2) were measured in 54 patients at baseline and after the first CT. Twenty-nine and 25 patients were randomly assigned to groups 1 and 2, respectively. Paclitaxel, when administered first, decreased the mean IFP by 36% (P = .02) and improved the tumor pO(2) by almost 100% (P = .003). In contrast, doxorubicin did not have a significant effect on either parameter. This difference was independent of the tumor size or response measured by ultrasound. CONCLUSION: Paclitaxel significantly decreased the IFP and increased the pO(2), whereas doxorubicin did not cause any significant changes. Tumor physiology could potentially be used to optimize the sequence of neoadjuvant CT in breast cancer. 相似文献
4.
Hanny Al-Samkari Aric D. Parnes Katayoon Goodarzi James I. Weitzman Jean M. Connors David J. Kuter 《Haematologica》2021,106(4):1148
Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing chemotherapy treatment delays, dose reductions, and discontinuation. There is no US Food and Drug Administration (FDA)-approved agent available to manage CIT. This study retrospectively evaluated patients with CIT treated on institutional romiplostim treatment pathways at four US centers. The primary outcome was achievement of a romiplostim response (median on-romiplostim platelet count ≥75x109/L and ≥30x109/L above baseline). Secondary outcomes included time to platelet count ≥100x109/L and rates of the following: platelet count <100×109/L, platelet count <75x109/L, platelet count <50x109/L, thrombocytosis, chemotherapy dose reduction/treatment delay, platelet transfusion, bleeding, and thromboembolism. Multivariable regression was used to identify predictors of romiplostim non-response and compare weekly dosing with intracycle/intermittent dosing. A total of 173 patients (153 solid tumor, 20 lymphoma or myeloma) were treated, with 170 (98%) receiving a median of four (range: 1-36) additional chemotherapy cycles on romiplostim. Romiplostim was effective in solid tumor patients: 71% of patients achieved a romiplostim response, 79% avoided chemotherapy dose reductions/treatment delays, and 89% avoided platelet transfusions. Median per-patient platelet count on romiplostim was significantly higher than baseline (116x109/L vs. 60x109/L; P<0.001). Bone marrow (BM) tumor invasion, prior pelvic irradiation, and prior temozolomide exposure predicted romiplostim non-response. Bleeding rates were lower than historical CIT cohorts and thrombosis rates were not elevated. Weekly dosing was superior to intracycle dosing with higher response rates and less chemotherapy dose reductions/treatment delays/bleeding; intracycle dosing had an incidence rate ratio (IRR) for dose reduction/treatment delay of 3.00 (95%CI: 1.30-6.91; P=0.010) and an IRR for bleeding of 4.84 (95%CI: 1.18-19.89, P=0.029) compared with weekly dosing. Blunted response (10% response rate) was seen in non-myeloid hematologic malignancy patients with BM involvement. In conclusion, romiplostim was safe and effective for CIT in most solid tumor patients. 相似文献
5.
Paolo Ventura Herbert L. Bonkovsky Laurent Gouya Paula Aguilera-Peir D. Montgomery Bissell Penelope E. Stein Manisha Balwani D. Karl E. Anderson Charles Parker David J. Kuter Susana Monroy Jeeyoung Oh Bruce Ritchie John J. Ko Zhaowei Hua Marianne T. Sweetser Eliane Sardh 《Liver international》2022,42(1):i-i
6.
Atul Mehta David J. Kuter Sam S. Salek Nadia Belmatoug Bruno Bembi Jeremy Bright Stephan vom Dahl Federica Deodato Maja Di Rocco Ozlem Göker‐Alpan Derralynn A. Hughes Elena A. Lukina Maciej Machaczka Eugen Mengel Aabha Nagral Kimitoshi Nakamura Aya Narita Beatriz Oliveri Gregory Pastores Jordi Pérez‐López Uma Ramaswami Ida V. Schwartz Jeff Szer Neal J. Weinreb Ari Zimran 《Internal medicine journal》2019,49(5):578-591
7.
Thrombopoietin (c-Mpl ligand) has recently been purified and is considered to be the humoral regulator of platelet production. To see whether this molecule possessed the physiologic characteristics necessary to mediate the feed-back loop between blood platelets and the bone marrow megakaryocytes, we determined the relationship between blood levels of thrombopoietin and changes in the circulating platelet mass. We developed a model of nonimmune thrombocytopenia in rabbits by the subcutaneous administration of busulfan. Compared with pretreatment plasma, plasma taken from all thrombocytopenic rabbits at their platelet nadir contained increased amounts of thrombopoietin. All of this activity was neutralized by soluble c-Mpl receptor. We subsequently measured the level of thrombopoietin in the circulation over the entire time course after the administration of busulfan. As the platelet mass declined, levels of thrombopoietin increased inversely and proportionally and peaked during the platelet nadir. With return of the platelet mass toward normal, thrombopoietin levels decreased accordingly. When platelets were transfused into thrombocytopenic rabbits near the time of their platelet count nadir, the elevated levels of thrombopoietin decreased. In addition, platelets were observed to remove thrombopoietin from thrombocytopenic plasma in vitro. These results confirm that thrombopoietin is the humoral mediator of megakaryocytopoiesis and suggest that the platelet mass may directly play a role in regulating the circulating levels of this factor. 相似文献
8.
Bonnie Ky Mary Putt Heloisa Sawaya Benjamin French James L. Januzzi Jr. Igal A. Sebag Juan Carlos Plana Victor Cohen Jose Banchs Joseph R. Carver Susan E. Wiegers Randolph P. Martin Michael H. Picard Robert E. Gerszten Elkan F. Halpern Jonathan Passeri Irene Kuter Marielle Scherrer-Crosbie 《Journal of the American College of Cardiology》2014
9.
10.
Li S Chan IS Matthews H Heyse JF Chan CY Kuter BJ Kaplan KM Vessey SJ Sadoff JC 《The Pediatric infectious disease journal》2002,21(4):337-342
BACKGROUND: We used the large clinical database that supported the development of Oka/ Merck varicella vaccine to study the relationship between the primary varicella antibody response, as determined by gpELISA, an enzyme-linked immunosorbent assay that detects antibodies to varicella-zoster virus (VZV) glycoprotein, and the subsequent risk of postvaccination breakthrough varicella. METHODS: We vaccinated 1,164 healthy children with a single dose of varicella vaccine containing 2900 to 9000 plaque-forming units/dose. The primary immune response to vaccination was determined by gpELISA 6 weeks after vaccination. Subjects were followed annually for 7 years to ascertain cases of breakthrough varicella. RESULTS: The estimated vaccine efficacy among children with a 6-week postvaccination antibody titer of > or = 5 gpELISA units was 95.5% (95% confidence interval, 94.2%, 96.8%) compared with 83.5% (95% confidence interval, 76.9%, 89.5%) for subjects with a titer of <5 gpELISA units. Children with a 6-week postvaccination antibody titer of <5 gpELISA units were 3.5 times more likely than those with a titer of > or = 5 gpELISA units to develop breakthrough varicella. CONCLUSIONS: We identified a 6-week postvaccination antibody titer of > or = 5 gpELISA units as an approximate correlate of protection. In addition we established an accelerated failure time model based on log normal hazard that predicted varicella breakthrough rates based on the distribution of 6-week postvaccination varicella antibody titers. 相似文献